CoChat

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Open access
Mancini, Maicol, Gal, Hilah, Gaborit, Nadège, Mazzeo, Luigi, Romaniello, Donatella, Salame, Tomer Meir, Lindzen, Moshit, Mahlknecht, Georg, Enuka, Yehoshua, Burton, Dominick GA, Roth, Lee, Noronha, Ashish, Marrocco, Ilaria, Adreka, Dan, Altstadter, Raya Eilam, Bousquet, Emilie, Downward, Julian, Maraver, Antonio, Krizhanovsky, Valery, Yarden, Yosef · 2018 · EMBO Molecular Medicine
Cited by 51

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second-site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M-EGFR, but several mechanisms, including a third-site mutation, C797S, confer renewed resistance. We previously reported that a triple mixture of monoclonal antibodies, 3×mAbs, simultaneously targeting EGFR, HER2, and HER3, inhibits T790M-expressing tumors. We now report that 3×mAbs, including a triplet containing cetuximab and trastuzumab, inhibits C797S-expressing tumors. Unlike osimertinib, which induces apoptosis, 3×mAbs promotes degradation of the three receptors and induces cellular senescence. Consistent with distinct mechanisms, treatments combining 3×mAbs plus sub-inhibitory doses of osimertinib synergistically and persistently eliminated tumors. Thus, oligoclonal antibodies, either alone or in combination with kinase inhibitors, might preempt repeated cycles of treatment and rapid emergence of resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201708076

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 51

Metadata

Authors
Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G., Roth, L., Noronha, A., Marrocco, I., Adreka, D., Altstadter, R. E., Bousquet, E., Downward, J., Maraver, A., Krizhanovsky, V., & Yarden, Y.
Venue
EMBO Molecular Medicine
Published
2017-12-06
Volume
10
Issue
2
Pages
294-308
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2773830451
Cited by
51
References
25
FWCI
3.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.